Coriolan Lebreton

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Newly Diagnosed

Metastatic Colorectal Cancer

Placebo Controlled

Top Venues

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Antonio Gonzáles Martin, María Jesús Rubio, Florian Heitz, René Depont Christensen, Nicoletta Colombo, Toon Van Gorp, Margarita Romeo Marin, Isabelle L Ray-Coquard, Lydia Gaba, Alexandra Leary, Luis Miguel De Sande, Coriolan Lebreton, Andrés Redondo, Michel Fabbro, Maria-Pilar Barretina Ginesta, Philippe Follana, José Alejandro Pérez-Fidalgo, Manuel J Rodrigues, Ana Santaballa, Renaud Sabatier, Maria José Bermejo-Pérez, Jean-Pierre Lotz, Beatriz Pardo, Gloria Marquina, Luisa Sanchez Lorenzo, María Quindós, Purificación Estévez-García, Eva Guerra Alía, Luis Manso Sanchez, Victoria Casado, Stefan Kommoss, Germana Tognon, Stéphanie Henry, Ilan Bruchim, Ana Oaknin, Frédéric Selle
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, Claire Cropet, Cristina Caballero, Pia Wolfrum-Ristau, Toyomi Satoh, Ignace Vergote, Gabriella Parma, Trine J Nøttrup, Coriolan Lebreton, Peter A Fasching, Carmela Pisano, Luis Manso, Hugues Bourgeois, Ingo Runnebaum, Claudio Zamagni, Anne-Claire Hardy-Bessard, Andreas Schnelzer, Michel Fabbro, Barbara Schmalfeldt, Dominique Berton, Antje Belau, Jean-Pierre Lotz, Martina Gropp-Meier, Laurence Gladieff, Hans-Joachim Lück, Sophie Abadie-Lacourtoisie, Eric Pujade-Lauraine, Isabelle L Ray-Coquard
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 34 (4) (2024)
Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, Claire Cropet, Cristina Caballero, Pia Wolfrum-Ristau, Toyomi Satoh, Ignace Vergote, Gabriella Parma, Trine J Nøttrup, Coriolan Lebreton, Peter A Fasching, Carmela Pisano, Luis Manso, Hugues Bourgeois, Ingo Runnebaum, Claudio Zamagni, Anne-Claire Hardy-Bessard, Andreas Schnelzer, Michel Fabbro, Barbara Schmalfeldt, Dominique Berton, Antje Belau, Jean-Pierre Lotz, Martina Gropp-Meier, Laurence Gladieff, Hans-Joachim Lück, Sophie Abadie-Lacourtoisie, Eric Pujade-Lauraine, Isabelle L Ray-Coquard
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 34 (4) (2024)
Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, Claire Cropet, Cristina Caballero, Pia Wolfrum-Ristau, Toyomi Satoh, Ignace Vergote, Gabriella Parma, Trine J Nøttrup, Coriolan Lebreton, Peter A Fasching, Carmela Pisano, Luis Manso, Hugues Bourgeois, Ingo Runnebaum, Claudio Zamagni, Anne-Claire Hardy-Bessard, Andreas Schnelzer, Michel Fabbro, Barbara Schmalfeldt, Dominique Berton, Antje Belau, Jean-Pierre Lotz, Martina Gropp-Meier, Laurence Gladieff, Hans-Joachim Lück, Sophie Abadie-Lacourtoisie, Eric Pujade-Lauraine, Isabelle L Ray-Coquard
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 34 (4) (2024)
Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, Lisa Belin, Katharina Leitner, David Cibula, Hannelore G Denys, Ora Rosengarten, Manuel J Rodrigues, Nikolaus de Gregorio, Jerónimo Martínez-Garcia, Edgar Petru, Roman Kocian, Ignace Vergote, Patricia Pautier, Barbara Schmalfeldt, Lydia Gaba, Stephan Polterauer, Marie-Ange Mouret Reynier, Jalid Sehouli, Cristina Churruca, Frédéric Selle, Florence Joly Lobbedez, Veronique D'Hondt, Émilie Bultot-Boissier, Coriolan Lebreton, Jean-Pierre Lotz, Rémy Largillier, Pierre Etienne Heudel, Florian Heitz, null null
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, Claire Cropet, Cristina Caballero, Pia Wolfrum-Ristau, Toyomi Satoh, Ignace Vergote, Gabriella Parma, Trine J Nøttrup, Coriolan Lebreton, Peter A Fasching, Carmela Pisano, Luis Manso, Hugues Bourgeois, Ingo Runnebaum, Claudio Zamagni, Anne-Claire Hardy-Bessard, Andreas Schnelzer, Michel Fabbro, Barbara Schmalfeldt, Dominique Berton, Antje Belau, Jean-Pierre Lotz, Martina Gropp-Meier, Laurence Gladieff, Hans-Joachim Lück, Sophie Abadie-Lacourtoisie, Eric Pujade-Lauraine, Isabelle L Ray-Coquard
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)